There's a window of time in our lives we've all passed through yet still know so little about: early gestation. Researchers ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

Navin Kundra: "River of life" Navin Kundra joins Scott Mills for today's Pause for Thought.

A new cohort study found that schizophrenia cases related to cannabis use disorder serious enough to warrant a person to seek emergency care increased afte ...

Caplyta is a prescription drug used to treat schizophrenia and bipolar disorder. Learn how long it takes the drug to work and how long it stays in your system.

A recent study published in the Journal of Psychopharmacology has offered encouraging preliminary findings for individuals ...

“These impairments often persist even during periods of symptom remission and can have a profound impact on daily functioning and quality of life,” says Caroline Fenkel, a doctor of social ...

In a notable Genomic Press research report, researchers at the Aristotle University of Thessaloniki have uncovered a significant presence of manic symptoms in patients with schizophrenia spectrum ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The proportion of incident cases of schizophrenia associated with cannabis use disorder (CUD) almost tripled from the prelegalization to legalization of ...

Research from Aristotle University of Thessaloniki, Greece reveals that over 26% of stable patients with schizophrenia ...

Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...

The proportion of schizophrenia cases associated with cannabis use disorder nearly tripled, rising from 4% pre-legalization to 10%, according to findings published Feb. 4 in JAMA Network Open.